MediVet America to Present Groundbreaking Study on Canine Stem Cell Therapy at the North American Veterinary Regenerative Medicine Association Conference

Share Article

The study, which also includes a blinded analysis completed at the University of Kentucky College of Medicine, profiles commercially available options currently available to treat canine, feline and equine patients with adipose (fat) derived stem cells. The study is the first of its kind to bring further discussion and analysis to the Stromal Vascular Fraction sample currently used in thousands of Veterinarian clinics across the country.

MediVet America, a Lexington, KY-based corporation known primarily as the World’s Leader in Veterinary Regenerative Medicine, will present a thirty-six manuscript study profiling the benefits of activated canine stem cells next month in Atlanta, GA. Dr. Michael Hutchinson will present on behalf of University of Kentucky professor, Dr. Don Cohen, findings and gene expression profiling of an activated stem cell sample. This special presentation will be held Tuesday, November 12th 2013 at 2:00 PM EST during the North American Veterinary Regenerative Medicine Conference (http://www.navrma.org).

The study which also includes a blinded analysis completed at the University of Kentucky College of Medicine profiles commercially available options currently available to treat canine, feline and equine patients with adipose (fat) derived stem cells. The study is the first of its kind to bring further discussion and analysis to the Stromal Vascular Fraction sample currently used in thousands of Veterinarian clinics across the country.

Each year, millions of animals suffer from debilitating Osteoarthritis that can leave an otherwise healthy animal facing euthanasia. Adult stem cells derived from fat tissue provide the potential for alleviation and most importantly the chance of repair of the animal’s diseased joints. The presentation titled “Gene Expression Profiling of Canine Adipose Derived Stem Cell Preparations: Effects of Tissue Preparations and Photo-activation” examines specifically targeted profiling of driving forces, scientifically behind the potential for repair as well as why not all commercially available “stem cell” procedures may be created equal.

This year, NAVRMA is taking place inside the Tissue Engineering and Regenerative Medicine International Society (TERMIS) Americas Annual Conference and Exposition. NAVRMA promotes the acquisition and distribution of knowledge regarding the emerging fields of regenerative medicine and stem cell therapy.

About MediVet America:

MediVet America began Research and Development in 2007 with commercialization of its in-clinic adipose derived stem cell therapy in 2010. MediVet founded the process which eliminated the delay in processing from an outside lab. The process allows a Veterinarian to harvest a small sample of fat tissue, process it down, activate and inject the cells same day in a clinic setting. MediVet America manufactures its own equipment to the specifications of the procedure and stores its customer’s animal stem cell cells on site to ensure quality.

This revolutionary procedure also is offered at one half the costs of traditional shipping services commercially available on the market. MediVet’s commitment to Research and Development continues to be strong with current studies underway on equine laminitis and an additional canine collaborative university project planned in the Spring of 2014.

For additional information, please email MediVet America at info(at)medivetamerica(dot)com or feel free to call us at 859-885-7111.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sarah Bernard
MediVet America
+1 859-885-7111 Ext: 309
Email >
Visit website